➤ Get the DrugPatentWatch Daily Briefing

Get Daily Updates on Generic Entry, Litigation, Biosimilars, and more …

Serving leading biopharmaceutical companies globally:

AstraZeneca
Baxter
Mallinckrodt
Medtronic
Merck
Express Scripts

Last Updated: June 13, 2021

DrugPatentWatch Database Preview

Litigation Details for PROMETHEUS LABORATORIES INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2011)


Email this page to a colleague

« Back to Dashboard

Small Molecule Drugs cited in PROMETHEUS LABORATORIES INC. v. ROXANE LABORATORIES, INC.
The small molecule drug covered by the patent cited in this case is   Get Started Free .

Details for PROMETHEUS LABORATORIES INC. v. ROXANE LABORATORIES, INC. (D.N.J. 2011)

Date Filed Document No. Description Snippet Link To Document
2013-10-14 238 Summary Judgment that the Claims of U.S. Patent No. 6,284,770 Are Not Invalid Under 35 U.S.C. 305 (MCCORMICK…2011 3 June 2014 2:11-cv-00230-KM-MAH Patent None District Court, D. New Jersey External link to document
2013-10-14 239 Summary Judgment that the Claims of U.S. Patent No. 6,284,770 Are Not Invalid Under 35 U.S.C. 305 /Declaration…2011 3 June 2014 2:11-cv-00230-KM-MAH Patent None District Court, D. New Jersey External link to document
2013-10-14 240 Summary Judgment that the Claims of U.S. Patent No. 6,284,770 Are Not Invalid Under 35 U.S.C. 305 /Defendants…2011 3 June 2014 2:11-cv-00230-KM-MAH Patent None District Court, D. New Jersey External link to document
2013-10-18 243 Summary Judgment that the Claims of U.S. Patent No. 6,284,770 Are Not Invalid Under 35 U.S.C. 305 (Attachments…2011 3 June 2014 2:11-cv-00230-KM-MAH Patent None District Court, D. New Jersey External link to document
2013-12-16 255 Defendants have or will infringe U.S. Patent No. 6,284,770 (“the ’770 patent”) under 35 U.S.C. §§ 271(a), 271…the ’770 patent “in response to a decision adverse to the patentability” of the ’770 patent, Prometheus…014 patent, and Cipla brings a motion for summary judgment seeking to invalidate the ’770 patent under… their dispute with respect to the ’014 patent. That patent is no longer at issue in this matter. …Defendants have or will infringe U.S. Patent No. 6,175,014 (“the ’014 patent”) under 35 U.S.C. §§ 271(b) and External link to document
>Date Filed >Document No. >Description >Snippet >Link To Document

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Dow
Colorcon
Harvard Business School
Boehringer Ingelheim
Mallinckrodt
Express Scripts

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.